AIM ImmunoTech (AIM) Registration Filing summary

Company overview and business model

• Focuses on developing immuno-pharma therapeutics for cancers, viral diseases, and immune-deficiency disorders with unmet needs.

• Lead products are Ampligen (dsRNA molecule) and Alferon N Injection (Interferon alfa); Ampligen is approved in Argentina for severe Chronic Fatigue Syndrome.

• Current R&D priorities include clinical trials for pancreatic cancer, studies in other solid tumors, antiviral applications (including COVID-19 and avian influenza), and post-COVID fatigue.

• Intellectual property is protected through patents, trademarks, and proprietary agreements.

Financial performance and metrics

• As of September 30, 2025, net tangible book value was approximately negative $8.1 million, or negative $2.94 per share.

• Pro forma net tangible book value after the offering would be $0.20 per share, with immediate dilution of $1.00 per share to new investors.

• Stockholders' deficit was approximately negative $6.1 million as of September 30, 2025.

Use of proceeds and capital allocation

• Net proceeds (estimated at $10.65 million if fully subscribed) will be used for general corporate purposes, clinical trial and manufacturing expenses for Phase 2/3 pancreatic cancer trials, and partial repayment of two unsecured notes (each originally ~$3.3 million).

• Proceeds from warrant exercises will be used similarly.

• Management has broad discretion over allocation of proceeds.